October 14, 2021 PAI Top-10

Roche’s Gazyvaro shorter 90-minute infusion time approved in Europe for people with previously treated or untreated follicular lymphoma

Basel, 14 October 2021 Short duration infusion of Gazyvaro® (obinutuzumab) is administered with a target infusion time of 90 minutes, compared to the current standard infusion time of approximately three to four hours Results from the phase IV GAZELLE study showed no new safety signals with the shorter infusion of Gazyvaro Shorter infusions could be... Read more

October 13, 2021 Clinical Research/Diagn. Licensing, IP, and Legal

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

SANTA CLARA, Calif., October 13, 2021  Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early breast cancer (EBC) at high risk of disease recurrence, for whom adjuvant treatment with Verzenio® (abemaciclib) in combination with endocrine therapy is being considered.... Read more

October 13, 2021 Clinical Research/Diagn. M&A, Partnerships

GE Healthcare Partners with Apprise Health Insights to Launch Nation's First Automated Statewide Hospital Bed Management Solution in Oregon

First-of-its-kind tool actively manages hospital data, providing near real-time occupancy information that enables hospitals to maximize resources Saved participating hospitals 45,000 hours of labor, amounting to $3 million dollars, by eliminating the need for manual entry of capacity data Puts actionable data in the hands of decision-makers so that statewide capacity can be optimized, allowing... Read more

October 13, 2021 Licensing, IP, and Legal

Data up to 8-years for Roche’s OCREVUS (ocrelizumab) show early and ongoing treatment significantly reduced risk of requiring a walking aid in relapsing multiple sclerosis and disability progression in primary progressive multiple sclerosis

35% reduction in risk of needing a walking aid in relapsing multiple sclerosis (RMS) after 7.5 years vs. initiation 2 years later in Phase III open-label extension (OLE) 29% reduction in 48-week confirmed disability progression in primary progressive MS (PPMS) after 8 years vs. initiation after double-blind period in Phase III OLE New 8-year safety... Read more

October 12, 2021 Informatics & Software M&A, Partnerships

Fluidigm Announces New Co-Marketing Program under Collaboration Agreement with Visiopharm, Offering AI-Based Image Analysis Software

Oct 12, 2021 Native Reading of Hyperion Imaging System Data Files on the Visiopharm Platform to Streamline Data Analysis for Researchers SOUTH SAN FRANCISCO, Calif., Oct. 12, 2021 (GLOBE NEWSWIRE) — Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced a new co-marketing program to offer Visiopharm® image... Read more

October 12, 2021 Liq. Handling & Robotics PR/Corporate

SPT Labtech integrates recent acquisitions into unified brand and portfolio

12/10/2021 SPT Labtech, a global leader in the design and development of automated instrumentation and consumables for life science applications, unveils new branding that brings together its technologies with those from recent acquisitions into a single entity. The merged portfolio and positioning reflect SPT Labtech’s commitment to harnessing the ingenuity and product development track record... Read more

October 12, 2021 Environ, Ag./Food & Bev Lab Top-10

Danaher Releases 2021 Sustainability Report; Building A Strong Foundation Of Sustainability

Danaher Releases 2021 Sustainability Report; Building A Strong Foundation Of Sustainability WASHINGTON, Oct. 12, 2021 /PRNewswire/ — Danaher Corporation (NYSE: DHR) (the “Company”), the global science and technology innovator, today released its 2021 Sustainability Report and highlighted the meaningful progress it has achieved in building a strong foundation of sustainability. Rainer Blair, President and CEO said,... Read more